Clearmind Medicine(CMND.US)

Last Updated 19:00:00 ET
longbridge loading

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications | CMND Stock News

StockTitan·
US
CMND
-38.04%
US
LLY
+2.72%
StockTitan·
US
CMND
-38.04%
US
LLY
+2.72%

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. | CMND Stock News

StockTitan·
US
CMND
-38.04%
US
VHT
+1.11%
US
BIB
+0.37%
StockTitan·
US
CMND
-38.04%
US
VHT
+1.11%
US
BIB
+0.37%

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News

StockTitan·
US
CMND
-38.04%
StockTitan·
US
CMND
-38.04%

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial | CMND Stock News

StockTitan·
US
CMND
-38.04%
US
ARKG
+0.28%
US
LABU
-1.22%
StockTitan·
US
CMND
-38.04%
US
ARKG
+0.28%
US
LABU
-1.22%

Clearmind Medicine shares are trading lower. The company announced filing of a European patent application for psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder and other mental health disorders.

benzinga_article·
US
CMND
-38.04%
benzinga_article·
US
CMND
-38.04%

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News

StockTitan·
US
CMND
-38.04%
StockTitan·
US
CMND
-38.04%
© 2026 Longbridge｜Disclaimer